

# Deciphering glycoprotein VI signalling in platelet activation

Citation for published version (APA):

Cheung, Y. F. H. (2023). *Deciphering glycoprotein VI signalling in platelet activation: integration of functional and computational modelling data*. [Doctoral Thesis, Maastricht University, University of Birmingham]. Maastricht University. <https://doi.org/10.26481/dis.20230927yc>

## Document status and date:

Published: 01/01/2023

## DOI:

[10.26481/dis.20230927yc](https://doi.org/10.26481/dis.20230927yc)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## ***Summary***

Cardiovascular diseases are the leading causes of mortality worldwide, and platelets are critical in their pathophysiology. Current antiplatelet therapies come with the risk of bleeding, so treatments targeting other platelet pathways that preserve haemostasis are needed. Two potential inter-related candidates being investigated in this thesis are the collagen and fibrinogen receptor glycoprotein VI (GPVI), which has a major role in thrombosis but a minor one in haemostasis; and phosphoinositides and their associated kinase/phosphatases, which are involved in  $\text{Ca}^{2+}$  mobilisation and regulation of pleckstrin homology domain-containing proteins. **Chapter 1** provides a general introduction to the knowledge of how platelets contribute to thrombosis and haemostasis, focusing on the roles of GPVI, GPVI-related signalling pathways, and the platelet phosphoinositide metabolism.

Current mass spectrometry-based methods to analyse phosphoinositides provide insufficient resolution of lipid isomers. In **Chapter 2**, we developed a sensitive ion chromatography-mass spectrometry (IC-MS)-based approach, and validated this from an analytical perspective. We demonstrate the reproducibility and efficiency of the used phosphoinositide extraction method by spiking in a phosphoinositide standard. We also optimised the IC gradient to achieve stable elution time and to improve isomer resolution, particularly for the six major positional isomers of phosphatidylinositol phosphate (PtdInsP) and phosphatidylinositol bisphosphate (PtdInsP<sub>2</sub>). The method has a linear range from 0.3-10 pmol, with a limit for detection for PtdIns(3,4,5)P<sub>3</sub> at 0.3 pmol, comparable with the literature. Application of the method showed adequate phosphoinositide detection in human platelets and other cells. Analysis of platelets using showed that treatment with the GPVI agonist, collagen-related peptide (CRP), leads to increased levels of (PtdIns4P), PtdIns(4,5)P<sub>2</sub>, PtdIns(3,4)P<sub>2</sub> and PtdIns(3,4,5)P<sub>3</sub>. This is consistent with previous findings.

To better understand the platelet phosphoinositide metabolism, in

**Chapter 3**, I developed mathematical models for prediction of molecular changes in platelets upon GPVI signalling. This concerned the CRP-induced changes of tyrosine phosphorylation of the membrane protein LAT and PLC $\gamma$ 2 (phospholipase C $\gamma$ 2), of altered Ca $^{2+}$  mobilisation, and changes in the levels of PtdIns(4,5)P $_2$ , PtdIns(3,4)P $_2$  and PtdIns(3,4,5)P $_3$ . Based on prior experimental data, each of the two mathematical models could simulate the changes over time of the phosphoinositide isomers. This model was able to predict the effects of inhibition of phosphatidylinositol 4-kinase A (PI4KA), but not of inositol polyphosphate-5-phosphatase (OCRL). The latter limitation we attributed to the specific localisation of OCRL in the Golgi system, thereby making it unable to convert all substrates. The Ca $^{2+}$  mobilisation prediction indicated that not only PtdIns(4,5)P $_2$  and Ins(3,4,5)P $_3$  regulate this process, but also other factors like extracellular Ca $^{2+}$  entry and Ca $^{2+}$  back-pumping by Ca $^{2+}$ -ATPases.

It has been debated to which extent the GPVI-induced platelet integrin  $\alpha$ IIb $\beta$ 3 activation is persistent or reversible. **Chapter 4** investigated the ability of small molecule inhibitors of the protein tyrosine kinases Src, Syk and Btk can disrupt GPVI signalling and cause platelet disaggregation. The results show a reversal of the CRP-induced phosphorylation of Syk, LAT, Btk and PLC $\gamma$ 2 by the secondary addition of Src or Syk inhibitor. However, the platelet aggregation process was only reversible upon inhibition of both GPVI signalling and secondary mediator (thromboxane A $_2$  and ADP) formation. Further, partial aggregation reversal was observed by combined inhibition of Src and integrin  $\alpha$ IIb $\beta$ 3, indicating that sustained aggregation requires continued  $\alpha$ IIb $\beta$ 3 outside-in signalling. Overall, the results suggest that the reversibility of platelet activation is a matter of experimental design and method.

**Chapter 5** describes a novel ordinary differential equation (ODE) based model and an agent-based model (ABM) to predict how the binding of platelet stimuli can lead to the clustering of receptors and the ensuing

signals generation. The model simulations suggest that the clustering of receptors like GPVI on the cell surface can be achieved through at least three mechanisms, including multimerisation of receptors, multivalent ligands and cytosolic crosslinkers, all of which can induce powerful downstream signals. To validate the two models, we used a set of novel GPVI ligands, next to the recently identified nanobody 2 (Nb2), namely the dimer Nb2-2 and the tetramer Nb2-4. We found that Nb2-2 is more potent than Nb2 in blocking collagen and CRP-induced platelet aggregation. On the other hand, Nb2-4 acts as a GPVI agonist, causing platelet aggregation and tyrosine phosphorylation, which processes could be antagonised by blockage of GPVI or by inhibition of tyrosine kinases. In addition, we observed that the Syk inhibitor PRT-060318 suppressed the agonist-induced clustering of CLEC-2. The same compound also synergised with threshold concentrations of other GPVI- or CLEC-2-blocking molecules. Together, this demonstrates the key role of Syk kinase in the GPVI and CLEC-2 clustering and activation.

Elevated cytosolic  $\text{Ca}^{2+}$  is involved in all functional responses of platelets. In **Chapter 6**, we compared the platelet  $\text{Ca}^{2+}$  rises in the presence of extracellular EGTA or  $\text{CaCl}_2$  to determine the relative contribution of  $\text{InsP}_3$ -induced  $\text{Ca}^{2+}$  mobilisation on one hand, and the extracellular  $\text{Ca}^{2+}$  entry on the other hand. In comparison to the stronger platelet agonists CRP and thrombin, we observed that the  $\text{Ca}^{2+}$  rises induced by the weaker agonists collagen and TRAP-6 were more dependent on secondary mediators ADP and thromboxane  $\text{A}_2$ . Especially when back-pumping  $\text{Ca}^{2+}$ -ATPases were blocked, we measured a very high  $\text{Ca}^{2+}$  entry ratio. Experiments to identify the major  $\text{Ca}^{2+}$  entry mechanisms identified key roles of the Orai1 ion channel and  $\text{Na}^+/\text{Ca}^{2+}$  exchange proteins, in response to GPVI and the PAR receptors for thrombin.

The conclusive **Chapter 7** discusses the findings and limitations of this thesis, and highlights the need for obtaining advanced computational models, which allow for the testing of promising anti-platelet drugs.